Rational transplant timing and dose of mesenchymal stromal cells in patients with acute myocardial infarction
Mesenchymal stromal cells (MSCs) are considered to have a modest benefit on left ventricular ejection fraction (LVEF) in patients with acute myocardial infarction (AMI). However, the optimal injection timing and dose needed to induce beneficial cardiac effects are unknown. The purpose of this meta-analysis was to identify an optimal MSC transplantation time and cell dose in the setting of AMI to achieve better clinical endpoints.
http://stemcellres.biomedcentral.com/articles/10.1186/s13287-016-0450-9
-
18. 04. 2017
MSCs for HBV-Related Acute-on-Chronic Liver Failure
-
10. 04. 2017
Stem cells used to treat erectile dysfunction
-
03. 04. 2017
Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia
-
27. 03. 2017
Mesenchymal stem cells in a murine ovalbumin asthma model
-
20. 03. 2017
Mesenchymal stem cells for lung melanoma metastases therapy